Related Experiment Videos
COL1A1 Sp1 polymorphism predicts perimenopausal and early postmenopausal spinal bone loss
H M MacDonald1, F A McGuigan, S A New
1Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, United Kingdom.
Summary
Women with the COLIA1 Sp1 "ss" genotype experience accelerated bone loss, particularly at the spine. Hormone-replacement therapy (HRT) may mitigate this increased risk of osteoporosis progression.
Area of Science:
- Genetics
- Bone Biology
- Osteoporosis Research
Background:
- Genetic factors significantly influence osteoporosis development, but specific susceptibility genes remain incompletely understood.
- A polymorphism in the COLIA1 gene's Spl binding site is linked to reduced bone mineral density (BMD) and increased fracture risk.
Purpose of the Study:
- To investigate the association between COLIA1 Sp1 alleles and early postmenopausal bone loss.
- To determine if COLIA1 genotype influences bone loss rates in a Scottish female cohort.
Main Methods:
- Longitudinal study of 734 Scottish women over 5-7 years.
- Bone loss measured by dual-energy X-ray absorptiometry (DXA) at the spine and hip.
- Genotyping for COLIA1 Sp1 polymorphism (SS, Ss, ss).
Main Results:
- In non-HRT users, 'ss' homozygotes showed significantly greater bone loss at the lumbar spine compared to other genotypes.
- A similar trend of increased bone loss was observed at the femoral neck in 'ss' homozygotes.
- COLIA1 genotype independently explained 3.0% of spine BMD variation, after accounting for age, weight, and baseline BMD.
Conclusions:
- Women homozygous for the COLIA1 Sp1 polymorphism are at increased risk of accelerated bone loss at the spine.
- The detrimental effect of the COLIA1 Sp1 'ss' genotype on bone loss may be counteracted by hormone-replacement therapy (HRT).